Pediatrics:规范化抗生素管理降低抗生素使用率

2014-12-14 MedSci MedSci原创译

过去单中心儿童抗生素管理计划(ASPs)的研究表明,ASPs能够有效降低抗生素使用率。但是研究证据不足。为了研究比较了规范化ASPs(ASP+)和无规范化ASP(ASP-)儿童医院中抗生素的使用情况,美国犹他大学附属儿童医院的Adam L. Hersh医生对31家独立儿童医院展开多中心调查。该研究发表于近日的Pediatrics上。研究者通过计算儿童医院内患儿每1000住院天数的治疗时间,评估AS

过去单中心儿童抗生素管理计划(ASPs)的研究表明,ASPs能够有效降低抗生素使用率。但是研究证据不足。

为了研究比较了规范化ASPs(ASP+)和无规范化ASP(ASP-)儿童医院中抗生素的使用情况,美国犹他大学附属儿童医院的Adam L. Hersh医生对31家独立儿童医院展开多中心调查。该研究发表于近日的Pediatrics上。

研究者通过计算儿童医院内患儿每1000住院天数的治疗时间,评估ASPs对抗生素使用的影响。研究者调查了2004-2012年ASP+和ASP-儿童医院内抗生素的平均使用情况,并根据2007年美国感染病协会指南开展ASPs的时间,划分为2004-2007年计划实施前和2007-2012年计划实施后这两组。将抗生素的使用与所有抗菌素进行比较,并且比较每种药物亚组中抗生素的使用情况。对于ASP+的医院,利用动态回归的间断时间系列方法,研究了计划开展前后平均每个月抗生素使用情况的改变。

结果发现,相比于计划实施之前,计划实施之后,即2007-2012年ASP+儿童医院内抗生素的平均使用数量远远小于ASP-医院。在进行单个研究时发现,9个ASP+医院中有8个显示抗生素使用率下降,每1000住院天数的治疗时间平均每个月下降5.7%。对抗生素进行亚组研究时发现,平均每月下降8.2%。

研究表明,儿童医院规范化的ASP能够够有效降低抗生素使用率。

原始出处:


Hersh, A.L., et al., Antimicrobial Stewardship Programs in Freestanding Children's Hospitals. Pediatrics, 2014.

本文是MedSci原创编译整理,欢迎转载! 转载请注明来源并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]
    2015-01-23 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1725700, encodeId=72f51e257007a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 23 10:00:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958396, encodeId=8160195839645, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Nov 13 06:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685135, encodeId=6e081685135d7, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 02 19:00:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636993, encodeId=75311636993b7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 13 09:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691311, encodeId=7c4516913114d, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Jan 13 05:00:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670872, encodeId=243f16e087246, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Wed Sep 02 08:00:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615899, encodeId=2b6c1615899ac, content=<a href='/topic/show?id=158826812c4' target=_blank style='color:#2F92EE;'>#使用率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26812, encryptionId=158826812c4, topicName=使用率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dee19693687, createdName=ms3830150583600765, createdTime=Tue Dec 16 04:00:00 CST 2014, time=2014-12-16, status=1, ipAttribution=)]

相关资讯

Pediatrics:儿童医院能提供镰状细胞病并发症更佳护理

一项回顾性研究提示,具有镰状细胞病(SCD)和急性胸痛综合征的青少年及年轻成人患者,在综合医院得到的护理与在儿童医院所得到的护理不尽相同。这项研究显示,在综合医院接受治疗的患者,气管插管的比率更高,且住院时间更长,但患者的30天再入院率并无差异。 研究者发现,急性胸痛综合征是SCD患者的主要死因,而血管闭塞性疼痛是导致患者住院的最常见原因。 此外,研究人员还注意